文献速递肿瘤 PET/CT骨显像与常规 SPECT核素与放射性配体治疗

68Ga-成纤维细胞活化蛋白抑制剂PET/CT提高中低级别肉瘤检出率并识别放射性药物治疗候选者

68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy.
PubMed 文献 · J Nucl Med · 2024-06-03

这项前瞻性观察性试验纳入200例骨与软组织肉瘤患者,比较68Ga-FAPI PET/CT与18F-FDG PET/CT(186/200,93%)在分期或再分期中的表现。低级别肉瘤和未定级肉瘤中,68Ga-FAPI的摄取、检出率和准确率优于18F-FDG。68Ga-FAPI PET标准识别出约半数转移性肉瘤患者符合FAP靶向放射性药物治疗条件。

要点

  • 低级别肉瘤中68Ga-FAPI摄取显著高于18F-FDG(10.4±8.5 vs 7.0±4.5,P=0.01)。
  • 未定级肉瘤中68Ga-FAPI摄取显著高于18F-FDG(22.3±12.5 vs 8.5±10.0,P=0.0004)。
  • 138例转移性肉瘤患者中62例(45%)符合FAP靶向放射性药物治疗条件。

核心结论

  • 在低级别和未定级肉瘤患者中,68Ga-FAPI PET的摄取、检出率和准确率优于18F-FDG PET。
  • 68Ga-FAPI PET标准识别出约半数肉瘤患者符合FAP靶向放射性药物治疗条件。

研究设计与样本

  • 前瞻性观察性试验纳入200例骨与软组织肉瘤患者,其中186/200(93%)接受了68Ga-FAPI PET/CT和18F-FDG PET/CT用于分期或再分期。
  • 采用Wilcoxon检验进行半定量评估,采用Spearman r相关分析68Ga-FAPI摄取强度与组织病理学分级及活检样本FAP表达的关系。
  • 通过PET/CT前后问卷调查研究68Ga-FAPI PET对临床管理的影响。

主要发现

  • 68Ga-FAPI摄取在肉瘤亚型间异质,摄取最高的3种肉瘤为孤立性纤维性肿瘤(24.7±11.9)、未分化多形性肉瘤(18.8±13.1)和平滑肌肉瘤(15.2±10.2)。
  • 低级别肉瘤中68Ga-FAPI摄取显著高于18F-FDG(10.4±8.5 vs 7.0±4.5,P=0.01)。
  • 未定级(NA)的潜在恶性中间型或不可预测肉瘤中68Ga-FAPI摄取显著高于18F-FDG(22.3±12.5 vs 8.5±10.0,P=0.0004),包括孤立性纤维性肿瘤。
  • 低级别肉瘤中68Ga-FAPI准确率高于18F-FDG(92.2 vs 80.0),NA肉瘤中准确率亦较高(96.9 vs 81.9)。
  • 68Ga-FAPI摄取与组织病理学FAP表达评分(n=89)呈中度相关(Spearman r=0.43,P<0.0002)。

关键数值与推荐

  • FAP靶向放射性药物治疗资格定义为所有肿瘤区域SUVmax大于10。
  • 138例转移性肉瘤患者中62例(45%)符合FAP靶向放射性药物治疗条件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fibroblast activation protein-α (FAP) is often highly expressed by sarcoma cells and by sarcoma-associated fibroblasts in the tumor microenvironment. This makes it a promising target for imaging and therapy. The level of FAP expression and the diagnostic value of 68Ga-FAP inhibitor (FAPI) PET for sarcoma subtypes are unknown. We assessed the diagnostic performance and accuracy of 68Ga-FAPI PET in various bone and soft-tissue sarcomas. Potential eligibility for FAP-targeted radiopharmaceutical therapy (FAP-RPT) was evaluated. Methods: This prospective observational trial enrolled 200 patients with bone and soft-tissue sarcoma who underwent 68Ga-FAPI PET/CT and 18F-FDG PET/CT (186/200, or 93%) for staging or restaging. The number of lesions detected and the uptake (SUVmax) of the primary tumor, lymph nodes, and visceral and bone metastases were analyzed. The Wilcoxon test was used for semiquantitative assessment. The association of 68Ga-FAPI uptake intensity, histopathologic grade, and FAP expression in sarcoma biopsy samples was analyzed using Spearman r correlation. The impact of 68Ga-FAPI PET on clinical management was investigated using questionnaires before and after PET/CT. Eligibility for FAP-RPT was defined by an SUVmax greater than 10 for all tumor regions. Results: 68Ga-FAPI uptake was heterogeneous among sarcoma subtypes. The 3 sarcoma entities with the highest uptake (mean SUVmax ± SD) were solitary fibrous tumor (24.7 ± 11.9), undifferentiated pleomorphic sarcoma (18.8 ± 13.1), and leiomyosarcoma (15.2 ± 10.2). Uptake of 68Ga-FAPI versus 18F-FDG was significantly higher in low-grade sarcomas (10.4 ± 8.5 vs. 7.0 ± 4.5, P = 0.01) and in potentially malignant intermediate or unpredictable sarcomas without a World Health Organization grade (not applicable [NA]; 22.3 ± 12.5 vs. 8.5 ± 10.0, P = 0.0004), including solitary fibrous tumor. The accuracy, as well as the detection rates, of 68Ga-FAPI was higher than that of 18F-FDG in low-grade sarcomas (accuracy, 92.2 vs. 80.0) and NA sarcomas (accuracy, 96.9 vs. 81.9). 68Ga-FAPI uptake and the histopathologic FAP expression score (n = 89) were moderately correlated (Spearman r = 0.43, P < 0.0002). Of 138 patients, 62 (45%) with metastatic sarcoma were eligible for FAP-RPT. Conclusion: In patients with low-grade and NA sarcomas, 68Ga-FAPI PET demonstrates uptake, detection rates, and accuracy superior to those of 18F-FDG PET. 68Ga-FAPI PET criteria identified eligibility for FAP-RPT in about half of sarcoma patients.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Lanzafame H, Mavroeidi IA, Pabst KM, et al. 68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy. J Nucl Med. 2024. PMID: 38724279. doi:10.2967/jnumed.123.267248

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。